Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce

Benzinga17:33

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

Yahoo FinanceJan 10 22:55

Recursion Pharmaceuticals Is Maintained at Overweight by Keybanc

Dow JonesJan 9 05:03 · Ratings

Recursion Pharmaceuticals Analyst Ratings

BenzingaJan 9 04:51 · Ratings

KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10

Futu NewsJan 8 20:34 · Ratings

KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating

MT NewswiresJan 8 20:31 · Ratings